“…The efficacy of IMiDs is well established in MM; although not included among standard therapeutic options, IMiDs were explored in MF setting about a decade ago: some retrospective studies in MF patients receiving these agents documented a higher response rate in the presence of mutations involving spliceosome SRSF2, U2AF1, ZRSR2 and SFRB1. 22,23 In this respect, a targeted high-throughput sequencing on PB of our patient, at the time of MF evolution, did not reveal any additional mutation. The IMiDs have demonstrated clinical activity in ameliorating anemia, thrombocytopenia and splenomegaly due to their anti-inflammatory, anti-proliferative and anti-angiogenic effects through inhibition of NF-kB mediated pro-inflammatory and apoptotic circulating cytokines, including IL-2R, IL-6, IL-10, IL-8, TGFβ and TNF-α, which are all significantly increased in MF patients.…”